drugset / Trial / NCT00192452
Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
RandomizedSingle-groupDouble-blindTreatment
Summary
\- The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8 infusions.
Timeline
- Start
- 2001-03
- Primary completion
- —
- Completion
- 2001-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siplizumab | Monoclonal antibody | 0.012 mg/kg | Intravenous |
| Subject | Siplizumab | Monoclonal antibody | 0.04 mg/kg | Intravenous |